Wire · operational-macro
COMP360 Psilocybin NDA Submitted to FDA for Treatment-Resistant Depression
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 November 2026 · Fusion42 review
COMP360, a psilocybin-based treatment, has had a New Drug Application (NDA) submitted to the US FDA for treatment-resistant depression, marking a significant step in regulatory approval for psychedelic therapies in mental health.
This Wire brief sits within Fusion42's coverage of Drug Discovery, and 5 sources have reported it between 21 Oct 2026 and 20 Nov 2026.
◆ ◆ The Wire takeaway
Psychedelic drug developers now face a clearer path to US market access following COMP360’s FDA NDA submission. You must prepare regulatory strategies to capitalise on emerging approval windows in mental health treatment.
◆ Coverage
5 sources · first reported 21 Oct 2026 · latest 20 Nov 2026
◆ Related on Wire
◆ Topics